InMed Pharmaceuticals logo

InMed PharmaceuticalsNASDAQ: INM

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Canada

IPO:

05 May 2014

Next earnings report:

15 August 2024

Last dividends:

N/A

Next dividends:

N/A
$2.12 M
-92%vs. 3y high
5%vs. sector
-vs. 3y high
-vs. sector
-95%vs. 3y high
19%vs. sector
-99%vs. 3y high
11%vs. sector

Price

after hours | 104 min ago
$0.25-$0.00(-0.98%)

Dividend

No data over the past 3 years
$1.17 M$1.79 M
$1.17 M-$1.72 M

Analysts recommendations

Institutional Ownership

INM Latest News

InMed to Present at the Emerging Growth Conference
newsfilecorp.com10 June 2024 Sentiment: -

Vancouver, British Columbia--(Newsfile Corp. - June 10, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates, today announced the Company will be presenting at the upcoming Emerging Growth Conference scheduled for June 12-13, 2024. InMed's CEO, Mr.

Why Is InMed Pharmaceuticals (INM) Stock Down 25% Today?
InvestorPlace25 October 2023 Sentiment: NEGATIVE

InMed Pharmaceuticals (NASDAQ: INM ) stock is falling on Wednesday after the pharmaceutical company's shares underwent a massive rally on Tuesday! INM stock was up 70.5% when normal trading hours ended on Tuesday.

Why Is InMed (INM) Stock Up 110% Today?
InvestorPlace24 October 2023 Sentiment: POSITIVE

Investors have seen some impressive moves in recent days in the world of micro-cap biotech stocks. Today, InMed (NASDAQ: INM ) is among the leading gainers in the market, surging more than 110% as of this writing.

What type of business is InMed Pharmaceuticals?

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

What sector is InMed Pharmaceuticals in?

InMed Pharmaceuticals is in the Healthcare sector

What industry is InMed Pharmaceuticals in?

InMed Pharmaceuticals is in the Biotechnology industry

What country is InMed Pharmaceuticals from?

InMed Pharmaceuticals is headquartered in Canada

When did InMed Pharmaceuticals go public?

InMed Pharmaceuticals initial public offering (IPO) was on 05 May 2014

What is InMed Pharmaceuticals website?

https://www.inmedpharma.com

Is InMed Pharmaceuticals in the S&P 500?

No, InMed Pharmaceuticals is not included in the S&P 500 index

Is InMed Pharmaceuticals in the NASDAQ 100?

No, InMed Pharmaceuticals is not included in the NASDAQ 100 index

Is InMed Pharmaceuticals in the Dow Jones?

No, InMed Pharmaceuticals is not included in the Dow Jones index

When does InMed Pharmaceuticals report earnings?

The next expected earnings date for InMed Pharmaceuticals is 15 August 2024